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High-fat diet (HFD) induces obesity. This study examined the effects of Shiitake mushroom on the prevention of alterations of
plasma lipid profiles, fat deposition, energy efficiency, and body fat index induced by HFD. Rats were given a low, medium, and
high (7, 20, 60 g/kg = LD-M, MD-M, HD-M) Shiitake mushroom powder in their high-fat (50% in kcal) diets for 6 weeks. The
results showed that the rats on the HD-M diet had the lowest body weight gain compared to MD-M and LD-M groups (P < 0.05).
The total fat deposition was significantly lower (−35%, P < 0.05) in rats fed an HD-M diet than that of HFD group. Interestingly,
plasma triacylglycerol (TAG) level was significantly lower (−55%, P < 0.05) in rats on HD-M than HFD. This study also revealed
the existence of negative correlations between the amount of Shiitake mushroom supplementation and body weight gain, plasma
TAG, and total fat masses.
1. Introduction
Obesity is a chronic health problem. It is predicted that
by 2015 approximately 2.3 billion adults will become over-
weight, and more than 700 million will be obese [1].
Obesity causes many complications including dyslipidaemia,
diabetes, hypertension, and heart disease. Recently, obesity
has also been associated with the increased incidence of
many cancers [2]. Dyslipidaemia is a pathological disorder,
and current evidence has highlighted not only total choles-
terol but also triacylglycerol (TAG) as lipid risk factors in
metabolic syndrome.
Recently, community awareness in nutrition as a corner-
stone for healthy life style has increased. Functional food is
a concept of nutrition, based on the role of reducing the risk
of disease. A food will be considered as a functional food if
it gives one or more benefits or positive effects to the body
beyond adequate nutritional effects in a way that is relevant
to either improve the stage of health and well-being and/or
reduce the risk of disease [3].
Shiitake mushrooms are the second most popular and the
third widely cultivated edible mushroom in the world [4].
Certain components of Shiitake mushroom have hypolipi-
daemic effect, such as eritadenine and β-glucan. Although it
has been reported that eritadenine extracted from Shiitake
mushroom has hypolipidaemic effect, most of these studies
emphasize on the mechanism in hypocholesterolaemic effect
[5–8] but not the effect on triglyceride. β-glucan from
Shiitake mushroom is a primarily soluble dietary fibre. β-
glucan also present at high levels in graminaceous crops
such as barley, rye, and oat and also in bacteria, fungi,
and edible mushrooms [9], but the structure can vary from
source to source. Studies have reported that oat β-glucan
can increase satiety, reduce food intake, delay nutrition
absorption, and reduce plasma lipid levels [10–12]. Although
mushroom has been shown to improve lipid profiles [13–
15], studies in this regard are incomplete. Some studies have
reported single-dose effect on obesity-associated metabolic
disorders using mushroom powder supplementation [13,
16–18]. However, no data are currently available on the
ability of Shiitake mushroom to affect food intake, body fat
deposition, and plasma triglyceride concentrations in a dose
response manner.
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Studies have shown that high-fat diet-induced obesity in
rodents can develop dyslipidaemia, insulin resistance, and
altered metabolic regulatory hormones [19–22]. The diet-
induced obese animal model mimics human obesity more
than other models such as genetic knockout mutants [23].
This study has systematically examined the effects of Shiitake
mushroom on plasma lipid profiles, various types of fat
depositions, energy efficiency, and body fat index as well as
their relationships in a dose-response manner in rats fed a
high-fat diet.
2. Material and Methods
2.1. Animals and Diet. All experimental procedures were
approved by the Animal Ethics Committee of the University
of Wollongong, AE 09/01. Forty Wistar rats, at 9 weeks of age,
were obtained from animal resource centre (ARC)-Perth,
Western Australia, and were given one week acclimatization
to their new environment. They were housed two per cage in
environmentally controlled conditions (temperature 22◦C,
light cycle from 06:00 to 18:00 hours, and dark cycle from
18:00 to 06:00 hours) and had ad libitum access to food
and water. All rats were fed standard laboratory nonpurified
diet (YS Feeds PTY-Ltd, Young, NSW, Australia) during the
acclimatization period. The forty rats were divided into four
groups (n = 10) and fed 50% high-fat diets with an addition
of nil, low, medium, or high-dose of Shiitake mushroom
powder (HFD, 7 g/kg LD-M, 20 g/kg MD-M, or 60 g/kg HD-
M, resp.). The dietary intervention was carried out for six
weeks. The food was produced from semisynthetic material
according to the recommendation of American Institute of
Nutrition AIN-93 for rodent [24]. HFD consisted of the
following (g/Kg): corn starch, 210 (Goodman Fielder, NSW,
Australia); sucrose, 175 (Bella-vista, NSW, Australia); copha,
105 (Peerless food, Victoria, Australia); lard, 105 (Fonterra
brand, Victoria, Australia); sunflower oil, 50 (Goodman
Fielder, NSW, Australia); gelatine, 50 (Sunny Hills, Qld, Aus-
tralia); casein, 128 (Fonterra LTD, Auckland, New Zealand);
fiber, 51 (Nature, Rosenberg, Germany); mineral, 67 (MP
Biomedical, Ohio, USA); vitamin, 13 (MP Biomedical,
Ohio, USA). This study used Shiitake mushroom powder
containing 30%β-glucan (w/w) analysed with a Megazyme
β-glucan Kit. Compositions of the four diets are shown in
Table 1.
2.2. Food Intake, Body Weight, and Body Composition. Ani-
mals were weighed weekly throughout the six-week inter-
vention period. Food intake was measured every 24 hours
by weighing the amount of total food (g) provided to the
rats and subtracting the remaining food (g) in the cage after
24 hours. Following the intervention period, rats were killed
via carbon dioxide asphyxiation. The white adipose tissue
(WAT) comprised of visceral fat (epididymal, perirenal, and
omental fat) and subcutaneous fat (inguinal fat) and brown
adipose tissue (BAT) were then dissected out and weighed.
The body fat index (BFI) was calculated as the total amount
of epididymal, perirenal, omental, and inguinal fat deposits
per 100 g body weight [25]. The energy efficiency ratio (EER)
Table 1: Composition of experimental diet.
Component
Group1
HFD LD-M MD-M HD-M
Carbohydrate (%) 32 33 33 34
Protein (%) 16 16 16 16
Fat (%) 50 49 49 48
Fibre (%) 2 2 2 3
Shiitake mushroom powder
% (wt : wt)
— 0.7 2 6
Energy density (kJ/g) 18.8 18.8 18.8 18.4
1
HFD: high-fat diet; LD-M: low-dose mushroom in HFD; MD-M: medium
mushroom in HFD; HD-M: high-dose mushroom in HFD.
was calculated by body weight gain (BWG) per the amount
of energy intake (g/kJ) [26].
2.3. Plasma Lipid Profile. Blood samples were obtained by
puncturing the right ventricle of heart after euthanasia and
were collected in ethylenediaminetetraacetic-acid- (EDTA-)
coated tubes and centrifuged at 3000× rpm at 22◦C for
25 minutes. High-density lipoprotein (HDL) was isolated
from plasma with dextran sulphate and magnesium chloride,
based on a modified method from Sjoblom and Eklund [27].
Total plasma cholesterol (TC), TAG and HDL cholesterol
were measured using the Konelab 20XT with Infinity reagent
from Thermo Fisher Scientific (Auburn NSW, Australia).
2.4. Statistical Analysis. Food intake, BWG, EER, BFI, adi-
pose tissue, and plasma lipids were presented as mean and
standard errors. Statistical analysis was performed using
SPSS software (version 17.0, SPSS Inc, Chicago, Ill, USA).
One-way ANOVAs were used, followed by a post hoc Tukey-
Kramer significant differences test for multiple comparisons
among the groups. Differences were considered significant
when P < 0.05.
3. Results
3.1. Food Intake, Body Weight, and Fat Deposition. No dif-
ferences in the amount of food or energy intake were found
among all groups (Table 2). This study found significant
effects of dietary intervention on body weight gain (F3,38 =
6.204, P = 0.002, Table 2). Rats on a high dose of Shiitake
mushroom diet (HD-M group) had −35% and −39% lower
body weight gains than rats on low- and medium-Shiitake
mushroom diets, respectively (P < 0.05). There was also
a trend of lower body weight gain in the HD-M group
compared with the HFD group (−23%, P = 0.077).
Overall, there were significant effects in total fat masses
due to dietary interventions (F3,38 = 4.355, P = 0.010,
Table 2). Rats on HD-M diet had significantly lower total fat
masses, −35% and −37%, than the HFD and LD-M groups,
respectively. Furthermore, HD-M group also had a trend of
lower fat accumulation than the MD-M group (−32%, P =
0.076, Figure 1). The white adipose tissue in MD-M group
was−35% and−37% lower than the HFD and LD-M groups,
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Table 2: Food intake, energy intake, body weight, and fat deposits of rats fed experimental diets for 6 weeks1.
Treatment group
ANOVA
HFD LD-M MD-M HD-M
Food intake (g/rat/day) 24± 0.5 24± 0.5 24± 0.6 23± 0.8 NS
Energy intake (kJ/rat/day) 455± 9 449± 9 448± 11 423± 14 NS
Body weight gain 129± 8a,b 141± 9b 150± 14b 92± 8a 0.002
Fat-pad masses (g)
Epididymal 11.2± 1.0a,b 12.1± 1.0b 11.4± 1.2a,b 7.9± 0.5a 0.014
Perirenal 14.2± 1.1a 14.3± 1.7a 12.8± 1.6a,b 8.7± 0.8b 0.015
Omental 8.4± 0.6a,b 10.5± 1.0a 8.5± 0.7a,b 6.7± 0.6b 0.009
Inguinal fat 8.6± 1.5a 6.8± 0.7a,b 8.2± 1.7a 4.2± 0.5b 0.012
Visceral fat 33.8± 2.3a,b 37.0± 3.7b 34.0± 3.7a,b 23.3± 1.7a 0.012
WAT 42.4± 3.4a 43.8± 4.3a 40.6± 4.5a,b 27.5± 2.1b 0.011
BAT 0.58± 0.05 0.52± 0.06 0.54± 0.05 0.44± 0.01 NS
Total fat masses 43.0± 3.4a 44.4± 4.3a 41.2± 4.5a,b 28.0± 2.1b 0.010
1
Values are means±SEM, n = 10. Within a row, values with different superscripts are significantly different, P < 0.05. Abbreviations used: HFD: high-fat diet;
LD-M: low-dose mushroom in HFD; MD-M: medium mushroom in HFD; HD-M, high-dose mushroom in HFD.
respectively (F3,38 = 4.340, both P < 0.05). The visceral
fat mass (epididymal + perirenal + omental) was the lowest
in the HD-M group among all groups (F3,38 = 4.215, P =
0.012, Table 2). Furthermore, HD-M group had significantly
lower perirenal (−39%) and inguinal fat (−52%) compared
to HFD group. Epididymal and omental fat masses were
29% and 21% lower in the HD-M group than HFD group
(P = 0, 05). No differences were found in the BAT masses
among all groups.
3.2. Body Fat Index (BFI) and Energy Efficiency Ratio (EER).
The BFI was significantly different between four diet groups
(F3,38 = 5.86; P = 0.002). Results showed that rats on a HD-
M diet had a significantly lower BFI than the rats on HFD,
LD-M, and MD-M diets (−35%, −33%, and −30%, resp.).
No differences were found in the BFI between the HFD, LD-
M, and MD-M groups (Figure 2). There was a significant
difference in EER among four diet groups (F = 5.425,
P = 0.004, Figure 3). The HD-M group had a significantly
lower EER than the LD-M and MD-M groups (−30% and
−34%, resp.) but was not significantly different from HFD.
Furthermore, there were no statistical differences in EER
between the HFD, LD-M, and MD-M groups.
3.3. Plasma Triacylglycerol, Cholesterol and HDL Concentra-
tions. There was a significant difference in plasma TAG levels
between the four groups (F3,38 = 7.445; P = 0.001). The rats
on the HD-M diet had significantly lower levels of TAG than
HFD, LD-M, and MD-M (−55%, −41%, and −46%, resp.).
There were no significant differences among the HFD, LD-
M, and MD-M groups (Figure 4). Plasma total cholesterol
levels did not differ between four groups (P = 0.125).
Although rats on an HD-M diet had the highest level of
plasma HDL, no statistical difference was found (HD-M:
HFD: LD-M: MD-M = 1.26± 0.01: 1.12± 0.02: 0.95± 0.02:
0.84± 0.01 mmol/L), respectively.
3.4. Association between the Dosages of Shiitake Mushroom
and BWG, WAT, Plasma Lipid, BFI, and EER. This study
found that the amount of Shiitake mushroom added in a
high-fat diet (50% fat in kcal) was negatively associated
with the BWG, WAT, TAG, BFI, and EER (Figure 5). No
statistical difference was found between the amount of
Shiitake mushroom diets and plasma cholesterol and HDL
concentrations (data not shown).
4. Discussion
This study showed that adding HD-M in a high-energy
diet containing 50% fat can significantly prevent total fat
deposition and significantly lower plasma TAG in rats
compared with no addition of Shiitake mushroom diet.
It was also found that plasma TAG-lowering effect was
negatively associated with the amount of Shiitake mushroom
supplementations and positively associated with the amount
of visceral fat. Studies have been carried out to test plasma
TAG-lowering effect by adding mushroom powder into the
diets. The results varied, where studies showed a significant
effect of lowering plasma TAG [14, 15, 18, 28, 29], whilst
other did not [17, 30, 31]. There are a few factors that
may explain these differing results. The first is related to
the amount of sucrose in the diet which can lead to a high
level of plasma TAG in rodents [17, 18]. High-sucrose diet
promotes a hyper-TAG plasma level by increasing hepatic
TAG secretion and decreasing TAG removal [32]. A previous
study has reported that if the sucrose amount in the diet
is greater than 40% from total energy, the increasing of
plasma TAG is difficult to prevent by enriched mushroom
powder diet [17]. In this study, the high-fat diet group as
controls supplied 15% sucrose from total energy. Second is
the amount of mushroom in the diet. Studies have shown
that adding less than 5% (wt : wt) mushroom powder in the
diet does not significantly decrease plasma TAG, irrespective
the sources [13, 14, 17, 18, 30, 31, 33], which is also what
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Figure 1: Total fat masses were measured after 6-week dietary
treatments in rats. Bars represent means± standard errors, n = 10.
abMeans not sharing a common letter are significantly different
among groups at P < 0.05.
we have found. Therefore, the ratio between the amount of
sucrose and enriched mushroom in the diet is important for
plasma TAG-lowering effect.
The duration of the dietary intervention using mush-
room powder seems less important as it is compared with
the dose. Some short-term studies, 3 to 5 weeks [18, 33],
reported a reduction of plasma TAG concentration, whilst
others [16–18] reported no effects. Likewise, the longer-
intervention studies, such as 6- to 10-week interventions, also
showed mixed results with some having no effect [31] and
others with positive outcomes to prevent increasing plasma
TAG levels [15, 30]. Hence, the dose of mushroom powder is
more important than duration of supplementation.
It is largely unreported to use fat masses as an indicator to
determine the effect of adding mushroom to a diet on body
weight gain. In animal studies, there are currently limited
data relating to the analysis of body fat masses. Kabir and
Kimura [30] reported that giving 5% Shiitake mushroom
and 5% Maitake mushroom for 8 weeks to spontaneous
hypertensive rats (HSRs) did not significantly lower adipose
tissue compared to control group. There is also a lack of study
to define the effect of mushrooms on total fat masses in the
human study. In this study, we have demonstrated that the
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Figure 2: Body fat index was measured after 6-week dietary
treatments in rats. Bars represent means± standard errors, n = 10.
abMeans not sharing a common letter are significantly different
among groups at P < 0.05.
high-dose Shiitake mushroom lowered total fat deposition.
In addition, there was a negative correlation between an
increased dosage of Shiitake mushroom and a lower body fat
index. Previous study reported that reducing of plasma TAG
is associated with the decrease of total fat masses as white
adipose tissue [34], which is consistent with our results.
Weight-loss interventions are commonly prescribed for
obesity to reduce risk factors associated with metabolic
disease. Studies from animal experiments showed various
results in terms of adding mushroom powder in diets
affecting body weight gain and obesity. For example, a study
[14] showed a decrease in body weight gain by 53% by adding
2% extracts of Agaricus Blazei mushroom in the diet for
6 weeks in diabetes mellitus Sprague-Dawley rats induced
by streptozotocin. Again, body weight gain was significantly
reduced by 25% when adding 20% Maitake mushroom
powder to a hypercholesterolemic diet for 25 weeks [33].
However, no statistical difference in body weight changes was
reported in ApoE−/− mice after being given a diet containing
3% Bunashimeji mushroom powder for 10 wks [31]. A
similar result also reported that additional 5% mushroom
powder in the diet for four or eight weeks had no effect on
lowering body weight gain in spontaneous hypertension rats
Journal of Obesity 5
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Figure 3: Energy efficiency ratio (EER) was measured after 6-week
dietary treatments in rats. Bars represent means ± standard errors,
n = 10. For each variable, labelled means without a common letter
differ, P < 0.05.
or male F344/DuCrj rats [17, 30]. It appears that different
species of animal respond differently in body weight gain
to the dietary intervention using mushroom powder. The
dosages less than 5% mushroom powder seem to be less likely
to give any favourable effect to prevent body weight gain. The
initial body weight and age of animal model seem to have no
affect on the outcome of mushroom treatment to prevent the
increase of body weight [16–18, 30].
This study showed that body weight gain was signifi-
cantly lower in the HD-M group than the MD-M and LD-
M groups. This suggests that there was a threshold effect in
terms of the amount of Shiitake mushroom intake for the
prevention of weight gain in rats on a high-fat diet. As an
estimate of HD-M diet in rats, 90 g mushroom powder per
day may be required for humans to prevent body weight gain
and lower TAG. However, this must be tested in humans
before the recommendation is given. On the other hand,
a low-dose mushroom diet may not be strong enough to
prevent weight gain. For example, studies have shown that
supplementation of the diet with 30 g Maitake mushroom
per day for 21 days did not achieve body weight lowering
effect in patients with moderate dyslipidaemia [35].
This study found a diet of HD-M significantly lowered
the energy efficiency ratio (EER) compared to LD-M and
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Figure 4: Plasma TAG level was measured after 6-week dietary
treatments in rats. Bars represent means± standard errors, n = 10.
For each variable, labelled means without a common letter differ,
P < 0.05.
MD-M diets. The HD-M also tended to lower EER when
compared with HFD. This is in agreement with a previous
study showing that high-dose Shiitake mushroom diet lowers
energy efficiency in rats on a high-fat diet as adding Maitake
mushroom (20%) into hypercholesterolemic diet for 4 weeks
reduces 27% energy efficiency in body weight gain in rats
[33]. Unfortunately, the study of this kind has not been
carried out in humans.
The exact mechanism is not clear how Shiitake mush-
room diet resulting in lowering body weight gain, fat masses
and plasma TAG. There are three possible mechanisms
worthwhile of considerations. Firstly, Shiitake mushroom
could increase the fat elimination into faeces. Shiitake
mushroom contains 30%β-glucan. As a soluble fibre, β-
glucan may enhance luminal viscosity, delay gastric empty-
ing, and/or reduce intestinal absorption. Hence, it decreases
fat absorption. Secondly, Shiitake mushroom could reduce
nonesterified fatty acid (NEFA) derived from TAG as a source
of adipose tissue. Lipolysis of chylomicron and VLDL-TAG
are major determinants of adipose tissue development, and
the reduced WAT may be affected by the low-NEFA source
that enters to adipose tissue. A low NEFA in adipose tissue is
6 Journal of Obesity
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Figure 5: Significant correlations were found between dosages and BWG (a), WAT (b), plasma TAG level (c), BFI (d), and (e) EER. BWG:
body weight gain; WAT: white adipose tissue; TAG: triacylglycerol; BFI: body fat index; EER: energy efficiency ratio.
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possibly affected by the activity of enzyme LPL as main gate
keeper entry into adipose tissue [34]. The overexpression of
LPL in muscle prevents HFD-induced lipid accumulation
in adipose tissue. Increased LPL in skeletal muscle leads
to an enhanced TAG storage in muscle and then diverts
lipoprotein TAG-derived NEFA away from storage in adipose
tissue to oxidation in the muscle [36]. Normally fat from
food is released into the circulation as lipoprotein-TAG
[34]. Thirdly, the possibility that eritadenine from Shiitake
mushroom could inhibit the release of triacylglycerol from
the liver. The eritadenine has been reported to inhibit the
production of phosphatidylcholine that influences the release
of VLDL and HDL from liver [5]. Studies showed that adding
eritadenine extracted from Shiitake mushroom in the diet
can decrease plasma TAG by 27% in a cholesterol diet,
20% in cholesterol free diet, and 2% in diet with choline
chloride added [5–7]. The 50 mg eritadenine per kg diet
was shown to be sufficient to elicit hypolipidaemic effect in
rats [8]. The concentration of eritadenine is about 0.36% in
Shiitake mushroom powder [37]. The HD-M diet used in
this study contains ∼200 mg/kg food. Since TAG was low in
HD-M diet, it will be interesting to examine TAG in various
organs to ensure its possible storage or exclusion. In view of
that, fat content in faecal, plasma NEFA concentration, and
accumulation of TAG in the liver and muscle will need to be
examined to verify its potential side effects.
In conclusion, adding high Shiitake mushroom in a
high-fat diet can prevent body weight gain, fat deposition,
and plasma TAG in rats, while further study is necessary
to elucidate the underlying mechanisms and the possibility
component of Shiitake mushroom of these important effects.
Thereby, it could be used as a functional food to prevent
obesity. This study encourages an effort pursuing human
clinical trial using Shiitake mushroom for prevention and
treatment of obesity and its related metabolic disorders.
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